ASX Share rice
Mon 17 May 2021 - 05:24:am (Sydney)

CGB Share Price

CANN GLOBAL LIMITEDCGBPharmaceuticals, Biotechnology & Life Sciences

CGB Company Information


Cann Global Limited




Drug Manufacturers-Specialty & Generic


133 Castlereagh Street Sydney NSW Australia 2000


61 2 8379 1832

Exec. Chairperson & Exec. Director of Bus. Devel.:

Ms. Pnina Feldman

CEO, MD & Exec. Director:

Mr. Sholom Dovber Feldman

Chief Operating Officer:

Ms. Marion Lesaffre

Director of Sales & Marketing:

Mr. Franc Zvonar

Company Sec.:

Mr. Alexander James Neuling BSc, FCA (ICAEW), ACIS

Company Overview:

Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. The company operates through Hemp and Medical Cannabis Products, and Mining Exploration and Evaluation segments. It grows and cultivates hemp and medical cannabis products; and provides plant-based food and skin care products. The company also engages in the exploration and development of bauxite. In addition, it holds interests in the South Johnstone Project located in Queensland; and the New England Bauxite Project located in the New South Wales. The company was formerly known as Queensland Bauxite Limited and changed its name to Cann Global Limited in January 2019. Cann Global Limited was incorporated in 2007 and is based in Sydney, Australia.

CGB Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


CGB CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


CGB Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Interest Expense:


Total Revenue:


Cost Of Revenue:


CGB Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Retained Earnings:


Good Will:




Total Current Liabilities:


Short-Term Debt:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


CGB Share Price History

CGB News

09 Mar, 2021
Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the Australian Patent Office ("IP Australia") has granted Australian Patent No. AU 2018210690 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.
11 Feb, 2021
It is a pleasure to report that the Cann Global Limited ( ASX:CGB ) is up 83% in the last quarter. But that doesn't...
05 Oct, 2020
Sholom Feldman has been the CEO of Cann Global Limited (ASX:CGB) since 2007, and this article will examine the...